Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept Extension for Diabetic Retinopathy (VOYAGE)
NCT04708145Phase 4Completed
- Sponsor
- Greater Houston Retina Research Center
- Start
- Jun 2021
- Primary completion
- Jul 2024
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 2
01
Overview
A Phase 4 trial of aflibercept in diabetic retinopathy (DR), sponsored by Greater Houston Retina Research Center. Started Jun 2021; status: completed.
02
Drugs
aflibercept
03
Conditions
diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT04708145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04708145.